Mangoceuticals (NASDAQ:MGRX) Issues Earnings Results

Mangoceuticals (NASDAQ:MGRX) announced its quarterly earnings data on Thursday. The company reported ($0.09) earnings per share (EPS) for the quarter, FiscalAI reports. Mangoceuticals had a negative net margin of 4,639.13% and a negative return on equity of 112.00%.

Mangoceuticals Stock Up 0.0%

Shares of NASDAQ MGRX opened at $0.53 on Friday. The firm has a 50-day moving average price of $0.42 and a 200 day moving average price of $0.41. Mangoceuticals has a 52 week low of $0.16 and a 52 week high of $2.75. The stock has a market capitalization of $9.16 million, a price-to-earnings ratio of -0.36 and a beta of 2.10.

Institutional Investors Weigh In On Mangoceuticals

A number of institutional investors and hedge funds have recently modified their holdings of MGRX. Geode Capital Management LLC raised its holdings in Mangoceuticals by 35.4% during the second quarter. Geode Capital Management LLC now owns 26,498 shares of the company’s stock worth $40,000 after purchasing an additional 6,928 shares during the last quarter. Jane Street Group LLC acquired a new stake in Mangoceuticals in the fourth quarter valued at $35,000. Armistice Capital LLC purchased a new position in shares of Mangoceuticals in the fourth quarter valued at $1,137,000. Boothbay Fund Management LLC purchased a new position in shares of Mangoceuticals in the fourth quarter valued at $28,000. Finally, Ikarian Capital LLC purchased a new position in shares of Mangoceuticals in the fourth quarter valued at $102,000. Institutional investors and hedge funds own 56.72% of the company’s stock.

Wall Street Analysts Forecast Growth

MGRX has been the subject of several analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Mangoceuticals in a report on Wednesday, June 24th. Wall Street Zen raised Mangoceuticals to a “sell” rating in a report on Saturday, July 25th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Mangoceuticals Company Profile

Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program.